TAXUS PERSEUS Small Vessel

Coronary Artery Disease Clinical Trial

— PERSEUS SV  

Official title:

A Prospective Evaluation in a Non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® ElementTM Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions in Small Vessels

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00489541
• Other study ID #: S2043
• Secondary ID: S2043-PIVOT-2006
• Status: Completed
• Phase: Phase 3
• First received: June 20, 2007
• Last updated: April 24, 2014
• Start date: July 2007
• Est. completion date: October 2013

Study information

• Verified date: April 2014
• Source: Boston Scientific Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of the TAXUS PERSEUS Small Vessel trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo atherosclerotic lesions of up to 20 mm in length in native coronary arteries of ≥ 2.25 mm to < 2.75 mm diameter.

Description:

This is a prospective, multi-center, single-arm superiority trial to assess the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System for the treatment of de novo atherosclerotic lesions of ≤20 mm in length in native coronary arteries with visual RVD of ≥ 2.25 mm to < 2.75 mm diameter.

Two hundred twenty-four (224) subjects will be treated with the TAXUS Element stent at a maximum of 35 clinical sites. Follow-up at 30 days, 9 months including angiography) and 1 year will be completed in all subjects enrolled in the study. Eligible subjects will have annual follow-up until 5 years post-index procedure.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 224
• Est. completion date: October 2013
• Est. primary completion date: June 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Clinical Inclusion Criteria:

• Subject is = 18 years old

• Eligible for percutaneous coronary intervention (PCI)

• Documented stable angina pectoris (Canadian Cardiovascular Society [CCS] Classification 1, 2, 3, or 4) or unstable angina pectoris (Braunwald Class IB-C, IIB-C, or IIIB-C), or documented silent ischemia

• Acceptable candidate for coronary artery bypass grafting (CABG)

• Left ventricular ejection fraction (LVEF) is = 30%

• Subject (or legal guardian) understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed

• Subject willing to comply with all specified follow-up evaluations

Clinical Exclusion Criteria:

• Contraindication to aspirin (ASA), or to both clopidogrel and ticlopidine

• Known hypersensitivity to paclitaxel

• Known allergy to stainless steel

• Known allergy to platinum

• Previous treatment of the target vessel with any anti-restenotic drug-coated or drug-eluting coronary stent

• Previous treatment of the target vessel with a bare metal stent (BMS) within 9 months of the index procedure

• Previous treatment of any non-target vessel with any anti-restenotic drug-coated or drug-eluting coronary stent within 9 months of the index procedure

• Previous treatment with intravascular brachytherapy in the target vessel

• Planned PCI or CABG post-index procedure

• Planned or actual target vessel treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon or transluminal extraction catheter immediately prior to stent placement

• Myocardial infarction (MI) within 72 hours prior to index procedure

• Cerebrovascular accident (CVA) within the past 6 months

• Cardiogenic shock

• Acute or chronic renal dysfunction

• Prior anaphylactic reaction to contrast agents

• Leukopenia

• Thrombocytopenia

• Thrombocytosis

• Active peptic ulcer or active gastrointestinal (GI) bleeding

• Current treatment, or past-treatment within 12-months of the index procedure, with paclitaxel or other chemotherapeutic agents

• Anticipated treatment with paclitaxel or oral rapamycin during any period in the 9-months after the index procedure

• Known intention to procreate within 9 months after the index procedure

• Positive pregnancy test within 7 days before the index procedure, or lactating

• Life expectancy of less than 24 months due to other medical conditions

• Co-morbid condition(s) that could limit subject's ability to comply with study follow-up requirements or impact study scientific integrity

• Currently participating in another investigational drug or device study

Angiographic Inclusion Criteria:

• Target Lesion

• Target lesion located in native coronary artery

• Target lesion must be de novo

• Target lesion diameter stenosis = 50%

• Reference vessel diameter (RVD) = 2.25 mm to < 2.75 mm

• Cumulative target lesion length = 20 mm (area to be treated may be composed of multiple lesions but must be completely coverable by one study stent)

• Target lesion is successfully pre-dilated

• One non-target lesion may be treated in a non-target vessel as follows:

• Non-target lesion in non-target vessel must be treated with commercially available TAXUS stent if use of drug eluting stent required

• Treatment must be deemed a clinical angiographic success, without requiring use of unplanned additional stents(s)

• Treatment must be completed prior to treatment of target vessel

Angiographic Exclusion Criteria:

• Target lesion located in left main artery, whether protected or unprotected

• Target lesion is a chronic total occlusion (TIMI flow = 1)

• Target lesion is restenotic

• Target lesion is located in a saphenous vein graft or mammary artery graft

• Target lesion is accessed via saphenous vein graft or mammary artery graft

• Target lesion is < 5 mm from bare metal stent (BMS)

• Target lesion < 5 mm from ostium

• Target lesion < 5 mm from side branch vessel = 2.0 mm in diameter (Exceptions:

subject may be enrolled if side branch is 100% occluded or if side branch is protected with a patent graft)

• Untreated lesions with = 50% diameter stenosis or thought to impair flow remaining in target vessel at a location with = 2.0mm RVD

• Target lesion and/or target vessel proximal to target lesion moderately severely calcified

• Target lesion and/or target vessel proximal to target lesion severely tortuous

• Target lesion located within or distal to a > 60° bend in target vessel

• Target vessel with angiographic presence of probable or definite thrombus

• Unprotected left main coronary artery disease

• Protected left main coronary artery disease with target lesion in Left Anterior Descending artery (LAD) or Left Circumflex artery (LCx). Subject may be enrolled if only lesion is target lesion in Right Coronary Artery (RCA)

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Device:
• Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation
TAXUS Element stent implantation

Locations

Country	Name	City	State
United States	Bakersfield Memorial Hospital	Bakersfield	California
United States	Medical Center East	Birmingham	Alabama
United States	Main Line Health Heart Center	Bryn Mawr	Pennsylvania
United States	Carolinas Medical Center	Charlotte	North Carolina
United States	The Christ Hospital	Cincinnati	Ohio
United States	Riverside Methodist Hospital	Columbus	Ohio
United States	Northern Indiana Research Alliance / Lutheran Hospital of Indiana	Fort Wayne	Indiana
United States	LeBauer Cardiovascular Research Foundation	Greensboro	North Carolina
United States	Methodist DeBakey Heart Center	Houston	Texas
United States	St. Mary's Medical Center	Huntington	West Virginia
United States	Scripps Clinic	La Jolla	California
United States	Nebraska Heart Hospital	Lincoln	Nebraska
United States	St. Joseph's Hospital Health Center	Liverpool	New York
United States	Abbott Northwestern Hospital	Minneapolis	Minnesota
United States	Columbia University Medical Center	New York	New York
United States	Lenox Hill Hospital	New York	New York
United States	Christiana Hospital	Newark	Delaware
United States	Mediquest Research at Munroe Regional Medical Center	Ocala	Florida
United States	Oklahoma Foundation for Cardiovascular Research	Oklahoma City	Oklahoma
United States	Cardiac & Vascular Research Center of Northern Michigan	Petoskey	Michigan
United States	Maine Medical Center	Portland	Maine
United States	Wake Medical Center	Raleigh	North Carolina
United States	TexSAn Heart Hospital	San Antonio	Texas
United States	Sarasota Memorial Hospital	Sarasota	Florida
United States	Swedish Medical Center	Seattle	Washington
United States	Sacred Heart Medical Center	Spokane	Washington
United States	St. John's Hospital	Springfield	Illinois
United States	Wake Forest University School of Medicine	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Boston Scientific Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	In-stent Late Loss Measured by Quantitative Coronary Angiography (QCA)	Post-procedure minimum lumen diameter (mm) minus follow-up minimum lumen diameter as determined by quantitative angiography. Minimum lumen diameter is measured within the stent at each time point.	9 months post-index procedure	Yes
Secondary	Number of Participants With Target Lesion Failure (TLF) at 12 Months Post-index Procedure. TLF is Defined as Any Ischemia-driven Revascularization of the Target Lesion, Myocardial Infarction (Q-wave and Non-Q-wave), or Death Related to the Target Vessel.	The number of participants who experience a TLF through 365 days post-procedure out of the patients who have either had a TLF within 365 days post-procedure or who were TLF-free with last follow-up at least 335 days post-procedure.	12 months post-index procedure	Yes